Kovack Advisors’s Gilead Sciences GILD Stock Holding History

Kovack Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-5	Closed	-$450K	–	465
2018 Q1	$450K	Buy	+5	New	+$397	0.11%	213
2017 Q4	–	Sell	-13	Closed	-$5K	–	473
2017 Q3	$5K	Buy	+13	New	+$994	﹤0.01%	344
2016 Q2	–	Sell	-4	Closed	-$1K	–	281
2016 Q1	$1K	Sell	4 -5	-56%	-$451	﹤0.01%	242
2015 Q4	$4K	Buy	9 +1	+13%	+$104	﹤0.01%	214
2015 Q3	$4K	Sell	8 -4	-33%	-$444	﹤0.01%	209
2015 Q2	$24K	Sell	12 -4	-25%	-$437	0.02%	198
2015 Q1	$17K	Sell	16 -7	-30%	-$711	0.01%	169
2014 Q4	$27K	Buy	+23	New	+$2.38K	0.03%	147

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kovack Advisors's GILD Position: Q1 2026 in Review

Kovack Advisors reduced its Gilead Sciences (GILD) stake by 30% in Q1 2026, selling an estimated $1.07M and leaving 17,794 shares worth $2.48M. The position accounts for 0.13% of the portfolio, ranked #146.

Kovack Advisors first reported a position in GILD in Q3 2014 and has held it in 46 quarters since. The position peaked at $3.12M in Q4 2025. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Kovack Advisors held 17,794 shares of Gilead Sciences worth $2.48M as of Q1 2026.
Kovack Advisors sold 7,627 Gilead Sciences shares in Q1 2026, an estimated $1.07M.
Gilead Sciences made up 0.13% of Kovack Advisors's portfolio in Q1 2026, its #146 holding.
Kovack Advisors first reported a position in Gilead Sciences in Q3 2014 and has held it in 46 quarters since.
Kovack Advisors's Gilead Sciences position peaked at $3.12M in Q4 2025.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.